Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company focusing on retinal diseases, has announced its participation in two major investor conferences in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9 and the Cantor 2024 Global Healthcare Conference on September 17.
CEO Frederic Guerard, PharmD, will deliver presentations at both events, with the H.C. Wainwright presentation scheduled for 7:00 AM ET and the Cantor presentation at 8:35 AM ET. Investors can access live webcasts of both presentations through provided links or via the 'Events & Presentations' section of Opthea's website.
These conferences offer Opthea an opportunity to showcase its progress in developing novel therapies for prevalent retinal diseases, including wet age-related macular degeneration (wet AMD).
Opthea (ASX/NASDAQ: OPT), un'azienda biofarmaceutica in fase clinica focalizzata sulle malattie retiniche, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settembre 2024. L'azienda presenterà al 26° Annual Global Investment Conference di H.C. Wainwright il 9 settembre e al Global Healthcare Conference di Cantor 2024 il 17 settembre.
Il CEO Frederic Guerard, PharmD, terrà presentazioni in entrambi gli eventi, con la presentazione di H.C. Wainwright programmata per le 7:00 AM ET e quella di Cantor alle 8:35 AM ET. Gli investitori possono accedere alle dirette delle due presentazioni tramite i link forniti o attraverso la sezione 'Eventi e Presentazioni' del sito web di Opthea.
Queste conferenze offrono a Opthea l'opportunità di mettere in mostra i suoi progressi nello sviluppo di nuove terapie per le malattie retiniche prevalenti, inclusa la degenerazione maculare legata all'età umida (wet AMD).
Opthea (ASX/NASDAQ: OPT), una empresa biofarmacéutica en etapa clínica centrada en enfermedades retinianas, ha anunciado su participación en dos importantes conferencias de inversores en septiembre de 2024. La empresa hará una presentación en la 26ª Conferencia Anual de Inversión Global de H.C. Wainwright el 9 de septiembre y en la Conferencia Global de Salud de Cantor 2024 el 17 de septiembre.
El CEO Frederic Guerard, PharmD, realizará presentaciones en ambos eventos, siendo la presentación de H.C. Wainwright a las 7:00 AM ET y la presentación de Cantor a las 8:35 AM ET. Los inversores pueden acceder a transmisiones en vivo de ambas presentaciones a través de los enlaces proporcionados o en la sección 'Eventos y Presentaciones' del sitio web de Opthea.
Estas conferencias ofrecen a Opthea la oportunidad de mostrar sus avances en el desarrollo de nuevas terapias para enfermedades retinianas prevalentes, incluida la degeneración macular relacionada con la edad húmeda (wet AMD).
옵티아 (ASX/NASDAQ: OPT), 망막 질환에 집중하는 임상 단계의 생명공학 회사가 2024년 9월에 두 개의 주요 투자자 회의에 참가한다고 발표했습니다. 이 회사는 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 9월 9일에 발표하고, 칸토 2024 글로벌 헬스케어 회의에 9월 17일에 발표할 예정입니다.
CEO 프레드릭 기라르(PharmD)는 두 행사에서 발표를 진행하며, H.C. 웨인라이트 발표는 오전 7:00 ET, 칸토 발표는 오전 8:35 ET로 예정되어 있습니다. 투자자들은 제공된 링크를 통해 또는 옵티아 웹사이트의 '이벤트 및 발표' 섹션을 통해 두 발표의 생중계에 접근할 수 있습니다.
이 회의는 옵티아가 습식 노인성 황반변성(wet AMD)을 포함한 일반적인 망막 질환을 위한 새로운 치료법 개발의 진전을 선보일 수 있는 기회를 제공합니다.
Opthea (ASX/NASDAQ: OPT), une entreprise biopharmaceutique en phase clinique spécialisée dans les maladies rétiniennes, a annoncé sa participation à deux grandes conférences pour investisseurs en septembre 2024. L'entreprise présentera à la 26e Conférence Annuelle Mondiale sur l'Investissement de H.C. Wainwright le 9 septembre et à la Conférence Mondiale sur la Santé de Cantor 2024 le 17 septembre.
Le PDG Frederic Guerard, PharmD, fera des présentations lors des deux événements, avec la présentation de H.C. Wainwright prévue à 7h00 ET et la présentation de Cantor à 8h35 ET. Les investisseurs peuvent accéder aux webdiffusions en direct des deux présentations via les liens fournis ou dans la section 'Événements et Présentations' du site Web d'Opthea.
Ces conférences offrent à Opthea l'occasion de mettre en avant ses avancées dans le développement de nouvelles thérapies pour les maladies rétiniennes courantes, y compris la dégénérescence maculaire liée à l'âge humide (wet AMD).
Opthea (ASX/NASDAQ: OPT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Netzhauterkrankungen konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2024 bekannt gegeben. Das Unternehmen wird am 26. Internationalen Global Investment Conference von H.C. Wainwright am 9. September und an der Cantor Global Healthcare Conference 2024 am 17. September teilnehmen.
CEO Frederic Guerard, PharmD, wird bei beiden Veranstaltungen Präsentationen halten, wobei die Präsentation von H.C. Wainwright um 7:00 Uhr ET und die Präsentation von Cantor um 8:35 Uhr ET geplant ist. Investoren können über die bereitgestellten Links oder im Bereich 'Veranstaltungen & Präsentationen' auf der Website von Opthea auf die Live-Übertragungen beider Präsentationen zugreifen.
Diese Konferenzen bieten Opthea die Gelegenheit, ihre Fortschritte bei der Entwicklung neuartiger Therapien für verbreitete Netzhauterkrankungen, einschließlich der feuchten altersbedingten Makuladegeneration (wet AMD), zu präsentieren.
- None.
- None.
MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present and participate in one-on-one investor meetings at the following two investor conferences in September 2024:
| H.C. Wainwright 26th Annual Global Investment Conference | |
| Presentation: | Monday, September 9, 2024, 7:00 AM ET |
| Presenter: | Frederic Guerard, PharmD, CEO |
| The webcast will be accessible via the link: https://journey.ct.events/view/19df556a-f376-4c6d-af5b-d8220d561640 | |
| Cantor 2024 Global Healthcare Conference | |
| Presentation: | Tuesday, September 17, 2024, 8:35 AM ET |
| Presenter: | Frederic Guerard, PharmD, CEO |
| The webcast will be accessible via the link: https://wsw.com/webcast/cantor22/register.aspx?conf=cantor22&page=opt&url=https://wsw.com/webcast/cantor22/opt/1938033, | |
The webcasts of both presentations can also be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, CEO
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
When is Opthea (OPT) presenting at the H.C. Wainwright Global Investment Conference in 2024?
What time is Opthea's (OPT) presentation at the Cantor 2024 Global Healthcare Conference?
Who will be presenting on behalf of Opthea (OPT) at the September 2024 investor conferences?
How can investors access Opthea's (OPT) presentations at the September 2024 conferences?
What is the main focus of Opthea's (OPT) clinical research?
